Jul. 2 at 3:57 AM
$SYRE This type of incremental innovation will never amount to anything. YTE is in the public domain. Literally anyone can do what they're doing.
If it were worth doing, believe me, the companies who own the innovative molecules would be making YTE versions (and maybe they are, we just don't know it yet).
They would have a massive edge in terms of understanding PK/PD of the YTE version, and could possibly go from phase 1 straight to phase 3. How funny would that be if we find out that Merck or Roche is already moving on a YTE TL1A phase 3? SYRE would go to
$5.
